Sarepta Therapeutics, Inc. will join Parent Project Muscular Dystrophy for a webinar update on Wednesday, May 9 at 1:00 PM EDT to discuss PPMO, Sarepta’s next generation precision RNA-targeting therapeutic platform for use in Duchenne muscular dystrophy.
Sarepta will also introduce their planned innovative enhancements to the trial design for their actively enrolling Phase 1 clinical trial, 5051-101, for their PPMO exon 51 candidate (SRP-5051, NCT: 03375255), and outline their plans for future development of additional exon targets.
- Pat Furlong
Founding President & CEO, Parent Project Muscular Dystrophy
- Doug Ingram
President and CEO, Sarepta Therapeutics, Inc.
Please submit questions in advance to email@example.com (subject line: Sarepta Webinar) by Monday, May 7 at 12pm eastern.